In recent stock market developments, HC Wainwright & Co. has reiterated its "Buy" rating for Immunic (IMUX, Financial). The investment firm, under the guidance of analyst Matthew Caufield, maintained its price target for IMUX at $10.00 USD. This decision reflects the continuation of their previous assessment of the stock.
The current price target of $10.00 USD by HC Wainwright & Co. aligns with their prior valuation, indicating no change in the firm's outlook towards Immunic (IMUX, Financial). The consistent rating at "Buy" suggests confidence in the company's potential performance in the market.
Investors are advised to take note of this reiteration by HC Wainwright & Co., as such affirmations can often influence investment strategies and decisions for those holding or considering acquiring stakes in Immunic (IMUX, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Immunic Inc (IMUX, Financial) is $14.83 with a high estimate of $28.00 and a low estimate of $6.00. The average target implies an upside of 1,224.40% from the current price of $1.12. More detailed estimate data can be found on the Immunic Inc (IMUX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Immunic Inc's (IMUX, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
